Doxribtimine (1 brand name, 1 dosage form, 1 route)
Available dosage forms: FOR SOLUTION.
Routes of administration: ORAL.
Brand Names
- KYGEVVI
Indications and Usage
KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
Contraindications
None.
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Elevated Liver Transaminase Levels [see Warnings and Precautions (5.1)] Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.2)]
Mechanism of Action
Administration of KYGEVVI is intended to incorporate the pyrimidine nucleosides, deoxycytidine and deoxythymidine, into skeletal muscle mitochondrial deoxyribonucleic acid (DNA). This action restores mitochondrial DNA copy number in TK2d mutant mice.